JP2011525477A - 免疫調節剤粒子および処置方法 - Google Patents

免疫調節剤粒子および処置方法 Download PDF

Info

Publication number
JP2011525477A
JP2011525477A JP2010549861A JP2010549861A JP2011525477A JP 2011525477 A JP2011525477 A JP 2011525477A JP 2010549861 A JP2010549861 A JP 2010549861A JP 2010549861 A JP2010549861 A JP 2010549861A JP 2011525477 A JP2011525477 A JP 2011525477A
Authority
JP
Japan
Prior art keywords
particles
protein
antigen
vaccine
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525477A5 (OSRAM
Inventor
ハビー，ボリン
マーフィー，アンドリュー
キンディグ，ジェフ
ホワイト，ジェス
ロス，サマンサ
ギャロウェイ，アシュリー
コップ，ローラ
Original Assignee
リクイディア・テクノロジーズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リクイディア・テクノロジーズ・インコーポレーテッド filed Critical リクイディア・テクノロジーズ・インコーポレーテッド
Publication of JP2011525477A publication Critical patent/JP2011525477A/ja
Publication of JP2011525477A5 publication Critical patent/JP2011525477A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2010549861A 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法 Pending JP2011525477A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6822708P 2008-03-04 2008-03-04
US61/068,227 2008-03-04
PCT/US2009/036068 WO2009111588A1 (en) 2008-03-04 2009-03-04 Immunomodulator particles and methods of treating

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014238952A Division JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Publications (2)

Publication Number Publication Date
JP2011525477A true JP2011525477A (ja) 2011-09-22
JP2011525477A5 JP2011525477A5 (OSRAM) 2012-04-26

Family

ID=41056361

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010549861A Pending JP2011525477A (ja) 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Country Status (5)

Country Link
US (2) US20110151015A1 (OSRAM)
EP (1) EP2262480B1 (OSRAM)
JP (2) JP2011525477A (OSRAM)
CN (1) CN102014874A (OSRAM)
WO (1) WO2009111588A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027571A2 (en) * 2006-08-30 2008-03-06 Liquidia Technologies, Inc. Nanoparticles having functional additives for self and directed assembly and methods of fabricating same
WO2008127455A2 (en) * 2006-12-05 2008-10-23 Liquidia Technologies, Inc. Nanoarrays and methods and materials for fabricating same
EP3269384A1 (en) 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
JP6282395B2 (ja) 2009-05-27 2018-02-21 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 異なる放出速度の構成要素を有するナノキャリア
US20130209564A1 (en) * 2010-02-22 2013-08-15 Shyam M. Rele Polysaccharide Particle Vaccines
NO2575876T3 (OSRAM) 2010-05-26 2018-05-05
US20130203675A1 (en) 2010-09-16 2013-08-08 Joseph M. DeSimone Asymmetric biofunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
US20130039954A1 (en) 2011-07-29 2013-02-14 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
EP2785326A2 (en) 2011-11-29 2014-10-08 The University of North Carolina at Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014165728A1 (en) * 2013-04-05 2014-10-09 The University Of North Carolina At Chapel Hill Particles having peg-ylated surfaces modified for lymphatic trafficking
DK3065771T3 (da) 2013-11-04 2019-06-11 Uti Lp Fremgangsmåder og sammensætninger til vedvarende immunterapi
KR102859521B1 (ko) 2015-05-06 2025-09-12 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
CN109069610A (zh) 2016-03-07 2018-12-21 葛兰素史密丝克莱恩生物有限公司 药物递送颗粒
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
CA3083748A1 (en) 2017-11-29 2019-06-06 Uti Limited Partnership Methods of treating autoimmune disease
EP4135769A4 (en) * 2020-04-16 2024-09-04 Emory University Immune cell redirecting compositions and therapeutic uses thereof
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083874A2 (en) * 2005-02-01 2006-08-10 Medivas, Llc. Vaccine delivery compositions and methods of use
WO2007024323A2 (en) * 2005-06-17 2007-03-01 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
GB9227068D0 (en) 1992-12-29 1993-02-24 British Bio Technology Novel proteinaceous particles
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
CA2314934C (en) * 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US6086881A (en) 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
DE69940353D1 (en) * 1998-11-11 2009-03-12 Univ Oklahoma Polymerpfropfung mittels polysaccharide-synthase
US6326021B1 (en) 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
JP4658423B2 (ja) 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
US20020061312A1 (en) 2000-07-31 2002-05-23 Ruslan Medzhitov Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
EP1401281A4 (en) 2001-05-09 2004-12-29 Univ Yale TOLL / INTERLEUKIN-1 RECEPTOR ADAPTER PROTEIN (TIRAP)
WO2003060153A2 (en) 2002-01-09 2003-07-24 Yale University Irak-m is a negative regulator of toll-like receptor signaling
WO2003059285A2 (en) 2002-01-09 2003-07-24 Yale University Rip2: a method of signaling in the innate and adaptive immune systems
WO2003087757A2 (en) * 2002-04-05 2003-10-23 Progenics Pharmaceuticals, Inc. Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
AU2003225054A1 (en) 2002-04-19 2003-11-03 Yale University Toll-like receptor 11 and toll-like receptor 12
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US7393493B2 (en) * 2003-02-27 2008-07-01 A Enterprises, Inc. Crosslinkable polymeric materials and their applications
US20050163764A1 (en) * 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20050118199A1 (en) * 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
CA2545276C (en) * 2003-11-05 2016-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
US9040090B2 (en) 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
KR101376715B1 (ko) * 2003-12-19 2014-03-27 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법
AU2005209303A1 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1951202A4 (en) 2005-11-07 2013-03-06 Univ North Carolina ISOLATED AND SOLID MICRO AND NANO STRUCTURES AND METHOD THEREFOR
WO2007081876A2 (en) * 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
US20090220789A1 (en) 2006-01-27 2009-09-03 The University Of North Carolina At Chapel Hill Taggants and methods and systems for fabricating same
KR20150038626A (ko) * 2006-03-17 2015-04-08 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
US20080181958A1 (en) * 2006-06-19 2008-07-31 Rothrock Ginger D Nanoparticle fabrication methods, systems, and materials
WO2008027571A2 (en) * 2006-08-30 2008-03-06 Liquidia Technologies, Inc. Nanoparticles having functional additives for self and directed assembly and methods of fabricating same
ES2517869T3 (es) * 2006-09-12 2014-11-04 Alphavax, Inc. Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos
US20100196277A1 (en) * 2006-10-09 2010-08-05 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
EP2146689B1 (en) * 2007-04-16 2020-08-12 Corium, Inc. Solvent-cast microneedle arrays containing active

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083874A2 (en) * 2005-02-01 2006-08-10 Medivas, Llc. Vaccine delivery compositions and methods of use
WO2007024323A2 (en) * 2005-06-17 2007-03-01 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
JPN6013035020; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ Ｖｏｌ．１０３，Ｎｏ．１３, 2006, ｐ４９３０-４９３４ *
JPN6013035022; Ｂｉｏｍａｔｅｒｉａｌｓ Ｖｏｌ．２８，Ｎｏ．３５, 2007, ｐ５３４４-５３５７ *
JPN6013035024; Ｎａｎｏｔｅｃｈｎｏｌｏｇｙ Ｖｏｌ．１６，Ｎｏ．４, 2005, ｐ４８４-４８７ *
JPN6013035026; 薬学雑誌 Ｖｏｌ．１２７，Ｎｏ．２, 2007, ｐ３０７-３１７ *
JPN6013035029; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｏｎｔｒｏｌｌｅｄ　Ｒｅｌｅａｓｅ Ｖｏｌ．１２１，Ｎｏ．１-２, 2007, ｐ１０-１８ *
JPN6013035031; Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ　Ｒｅｖｉｅｗｓ Ｖｏｌ．３５，Ｎｏ．１１, 2006, ｐ１０９５-１１０４ *
JPN6013035033; Ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　Ａｍｅｒｉｃａｎ　Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ Ｖｏｌ．１２７，Ｎｏ．２８, 2005, ｐ１００９６-１０１００ *
JPN6013035036; Ｐｏｌｙｍｅｒ　Ｒｅｖｉｅｗｓ Ｖｏｌ．４７，Ｎｏ．３, 2007, ｐ３２１-３２７ *
JPN6013035038; Ｐｈａｒｍａｚｉｅ Ｖｏｌ．５９，Ｎｏ．９, 2004, ｐ７２３-７２５ *
JPN6013035041; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｏｎｔｒｏｌｌｅｄ　Ｒｅｌｅａｓｅ Ｖｏｌ．８５，Ｎｏ．１-３, 2002, ｐ２４７-２６２ *
JPN6013035043; Ｉｎｆｅｃｔｉｏｎ　ａｎｄ　Ｉｍｍｕｎｉｔｙ Ｖｏｌ．７４，Ｎｏ．８, 2006, ｐ４９５４-４９５９ *
JPN6013035044; Ａｒｃｈｉｖｅｓ　ｏｆ　Ｐｈａｒｍａｃａｌ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．３０，Ｎｏ．８, 2007, ｐ１０４７-１０５０ *
JPN6013035046; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．６０，Ｎｏ．１４, 2000, ｐ３８３２-３８３７ *
JPN6013035047; Ｖａｃｃｉｎｅ Ｖｏｌ．２４，Ｎｏ．１１, 2006, ｐ１７３６-１７４３ *

Also Published As

Publication number Publication date
EP2262480A1 (en) 2010-12-22
US20110151015A1 (en) 2011-06-23
WO2009111588A1 (en) 2009-09-11
EP2262480A4 (en) 2012-03-14
CN102014874A (zh) 2011-04-13
JP2015078204A (ja) 2015-04-23
US20150273079A1 (en) 2015-10-01
EP2262480B1 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
EP2262480B1 (en) Immunomodulator particles
RU2379028C2 (ru) Композиция, стимулирующая иммунный ответ, содержащая наночастицы на основе сополимера метилвинилового эфира малеинового ангидрида
JP6434995B2 (ja) 界面活性剤を含まない水中油エマルジョン及びその用途
Skwarczynski et al. Peptide-based subunit nanovaccines
Azuar et al. Poly (hydrophobic amino acid)-based self-adjuvanting nanoparticles for Group A Streptococcus vaccine delivery
Zhang et al. A comparative study of the antigen‐specific immune response induced by co‐delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles
Gómez et al. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis
Uddin et al. Overview and future potential of fast dissolving buccal films as drug delivery system for vaccines
Yadav et al. Nanovaccines formulation and applications-a review
JP5050144B2 (ja) アジュバントとしてのポリアミノ酸
US11628208B2 (en) System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
Beg et al. Colloidal drug delivery systems in vaccine delivery
Dewangan et al. A review on application of nanoadjuvant as delivery system
CA2868455C (en) Antigenic compositions and methods
US20200054571A1 (en) Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles
Gupta et al. Adjuvants in micro‐to nanoscale: current state and future direction
Scheiblhofer et al. Potential of nanoparticles for allergen-specific immunotherapy–use of silica nanoparticles as vaccination platform
CA2862194C (en) Inulin and inulin acetate formulations
Hu et al. Toll-like receptor 9 agonists as adjuvants for nanoparticle-based nicotine vaccine
MuZikova et al. Macromolecular systems for vaccine delivery
Mishra et al. Surface modified nanoparticulate carrier constructs for oral mucosal vaccine delivery
HK1156253A (en) Immunomodulator particles and methods of treating
Patel et al. Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment
Shaikh et al. Effective Strategy for Delivering Nano-Liposomal Encapsulated Mycobacterial ESAT-6 Vaccine Adjuvant in Tuberculosis: Optimization, Characterization, and Preclinical Evaluation of Pharmaceutical Nanoparticles
Mody et al. Microparticles for Vaccine Delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140729